Clinical Trial Update: IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating IO102-IO103 in combination with pembrolizumab for high-risk non-muscle invasive bladder cancer that is unresponsive or intoler…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Non-muscle Invasive Bladder Cancer
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• IO102-IO103 (IO102-IO103)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of California, Davis | Conditions: High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8 | Phase 1 | Status: RECRUITING